Sitchon to highlight S1 Biopharma focus on central nervous system role in issues associated with sexual function and sexual wellness. NEW YORK, March 2, 2021 /PRNewswire/ — S1 Biopharma, Inc. (S1), a clinical stage company advancing therapies based on central…
Event focused on cross-border deals between the U.S. and China in the health sciences sector to be held January 8, 2019 in San Francisco, coinciding with 37th Annual J.P. Morgan Healthcare Conference New York, NY – Jan. 4, 2019 –…
New York, NY – Jan. 4, 2019 – S1 Biopharma, Inc. (S1) announced today that researchers will present an expanded analysis of data from the company’s Phase 2a clinical trial of Lorexys™ for the treatment of women with hypoactive sexual…
Newest patents significantly strengthen S1 intellectual property position New York, NY – December 20, 2018 – S1 Biopharma, Inc. (S1) announced today that the European Patent Office has granted a European Patent for the Company’s proprietary dual-mechanistic therapy Lorexys™ for…
Deal advances S1 Biopharma strategy for global commercialization of Lorexys. NEW YORK, Dec. 8, 2015 /PRNewswire/ — S1 Biopharma, Inc. a leading developer of first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women…
Mr. Sitchon will present an update on S1 Biopharma’s clinical stage development programs targeting treatment of diminished sexual desire in women and men. NEW YORK, Nov. 2, 2015 /PRNewswire/ — S1 Biopharma, Inc., a leading developer of first-in-class drugs for…
Expert on female sexual dysfunction disorder and CNS drug safety to outline challenges in development of combination therapies for CNS disorders. NEW YORK, Oct. 31, 2015 /PRNewswire/ — S1 Biopharma, Inc., a leading developer of first-in-class drugs for the treatment of sexual…
NEW YORK, June 5, 2015 /PRNewswire/ — Yesterday’s FDA Advisory Committee recommendation for the approval of flibanserin was a landmark step for women’s health, addressing the important unmet medical need for women living with hypoactive sexual desire disorder, or HSDD.…
JERSEY CITY, N.J., March 3, 2014 /PRNewswire/ — S1 Biopharma today announced its plan to initiate Phase 2a clinical trials in the third quarter of this year for Orexa (S1P-205), its first-in-class therapy to treat male Hypoactive Sexual Desire Disorder…
Activity of Lorexys Requires Precise Ratio of Active Components, Trazodone and Bupropion JERSEY CITY, N.J., July 29, 2013 — S1 Biopharma, Inc., a developer of first-in-class drugs for sexual dysfunction in women and men, today announced enrollment and dosing of premenopausal…